• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Invivyd Announces NEJM Publishes Immunobridging for Pemgarda

    GLOBENEWSWIRE

    Invivyd Reports Q3 2024 Financial Results & Highlights

    GLOBENEWSWIRE

    Invivyd to Host Q3 2024 Financial Results & Update Conference Call

    GLOBENEWSWIRE

    Invivyd Phase 3 Data Shows PEMGARDA™ Protects Against COVID-19

    GLOBENEWSWIRE

    Invivyd Reports Q3 2024 Results, Withdraws Financial Guidance

    GLOBENEWSWIRE

    Invivyd Presents PEMGARDA™ Data At Infectious Disease Week 2024

    GLOBENEWSWIRE

    Invivyd Updates PEMGARDA™ EUA Fact Sheet with Variant Data

    GLOBENEWSWIRE

    Invivyd Shares PEMGARDA SARS-CoV-2 Neutralization Data

    GLOBENEWSWIRE

    Invivyd Ready With PEMGARDA For COVID-19 Protection In Immunocompromised

    GLOBENEWSWIRE

    Invivyd to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    Invivyd Doses First Participants In VYD2311 Phase 1 Trial

    GLOBENEWSWIRE

    Invivyd Reports Continued Activity of PEMGARDA Against SARS-CoV-2 Variants

    GLOBENEWSWIRE

    Invivyd Reports Phase III Data For COVID-19 Prophylactic With Limited Protection

    ENDPTS

    Invivyd Reports Q2 2024 Financial Results And Business Highlights

    GLOBENEWSWIRE

    Invivyd To Host Q2 2024 Results And Business Highlights Call

    GLOBENEWSWIRE

    Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

    GLOBENEWSWIRE

    Invivyd Reports VYD222 Activity Against New SARS-CoV-2 Variants

    GLOBENEWSWIRE

    Invivyd to Participate at the Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Invivyd Aligns With FDA On Expedited COVID EUA Pathway For Monoclonal Abs

    GLOBENEWSWIRE

    Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

    GLOBENEWSWIRE

    Invivyd At ASCO And American Transplant Congress 2024

    GLOBENEWSWIRE

    Invivyd Elects Two New Independent Members to its Board of Directors

    GLOBENEWSWIRE

    Invivyd At HC Wainwright BioConnect Conference

    GLOBENEWSWIRE

    Invivyd Q1 2024 Financials And Business Highlights

    GLOBENEWSWIRE

    Invivyd Pursuing Rapid Immunobridging For COVID-19 EUA

    GLOBENEWSWIRE

    Invivyd Q1 2024 Results, Business Highlights Call

    GLOBENEWSWIRE

    Invivyd Projects $20-25M Higher 2024 Year-End Cash

    GLOBENEWSWIRE

    Invivyd Gets HCPCS Codes For PEMGARDA™ From CMS

    GLOBENEWSWIRE

    Invivyd Announces CEO Transition

    GLOBENEWSWIRE

    Invivyd Provides PEMGARDA Launch Update

    GLOBENEWSWIRE

    Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

    GLOBENEWSWIRE

    Invivyd`s COVID prophylactic scores FDA emergency nod

    FIERCE PHARMA

    Invivyd Announces FDA Authorization for Emergency Use PEMGARDA (Formerly VYD222

    GLOBENEWSWIRE

    Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Trial

    GLOBENEWSWIRE

    Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Conference

    GLOBENEWSWIRE

    Invivyd Submits Request for EUA to U.S. FDA for VYD222

    GLOBENEWSWIRE

    Invivyd requests emergency use authorization for Covid-19 preventive antibody

    ENDPTS

    Invivyd Announces Results from Phase 3 Trial Investigating VYD222

    GLOBENEWSWIRE

    Covid biotech’s stock jumps after positive PIII monoclonal antibody data reveal

    ENDPTS

    Invivyd Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Invivyd to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    Invivyd Announces Dosing of First Participant in Phase 3 Investigating VYD222

    GLOBENEWSWIRE

    Invivyd to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

    GLOBENEWSWIRE

    Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Invivyd Announces Appointment of Sara Cotter to Board Of Directors

    GLOBENEWSWIRE

    Invivyd Announces Additional Positive Data from Ongoing Phase 1 Trial of VYD222

    GLOBENEWSWIRE

    Invivyd Announces Alignment with FDA on Pathway to Potential EUA for VYD222

    GLOBENEWSWIRE

    Invivyd, FDA agree on steps to EUA for COVID monoclonal antibody

    FIERCE BIOTECH

    Invivyd reports positive results from trial of antibody for Covid-19

    CLINICAL TRIALS ARENA

    Invivyd Announces Positive Initial Data from Ongoing Ph1 Trial of VYD222

    GLOBENEWSWIRE

    Invivyd to Participate at the Jefferies Healthcare Conference

    GLOBENEWSWIRE

    Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

    GLOBENEWSWIRE

    Invivyd to Host Conference Call Discussing 1Q 2023 FYR and Business Highlights

    GLOBENEWSWIRE

    Invivyd Announces the FDA Has Cleared Its IND Application for VYD222

    GLOBENEWSWIRE

    Invivyd to Participate at H.C. Wainwrightâ BioConnect Investor Conference

    GLOBENEWSWIRE

    Invivyd Appoints Robert Allen as CSO and Stacy Price as Chief Technology Officer

    GLOBENEWSWIRE

    Invivyd Doses First Participants in Phase 1 Trial of VYD222

    GLOBENEWSWIRE

    Invivyd Reports Full Year 2022 Financial Results and Business Highlights

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.